14-day Premium Trial Subscription Sign Up For FreeGet Free
Stock Market Ideas | Artificial Intelligence companies Click To Watch.

$1.23 (-7.52%)

Volume: 191.173k

Closed: Sep 23, 2022

Hollow Logo Score: -3.753

Cyclacel Pharmaceuticals Stock Forecast

$1.23 (-7.52%)

Volume: 191.173k

Closed: Sep 23, 2022

Score Hollow Logo -3.753

Cyclacel Pharmaceuticals Company Profile

200 Connell Drive, Suite 1500

Berkeley Heights NJ 07922

908 517 7330

www.cyclacel.com

Industry: Biotechnology

Sector: Healthcare

Cyclacel Pharmaceuticals

Description

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

Hot Stocks To Watch:

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE